Claims
- 1. A method of inhibiting stenosis formation at a site of trauma in a blood vessel, comprising:
administering to said vessel a composition comprising an antirestenotic compound conjugated to a microparticle carrier; wherein the antirestenotic compound is selected from the group consisting of rapamycin, tacrolimus, paclitaxel, active analogs or derivatives or prodrugs thereof, and combinations thereof, and the microparticle carrier comprises a suspension of insoluble gas-containing microbubbles or biocompatible polymeric microparticles in a pharmaceutically acceptable liquid vehicle.
- 2. The method of claim 1, wherein said administration is carried out prior to, during, and/or following a procedure selected from balloon angioplasty, stent implantation, and surgical incision or grafting of the vessel.
- 3. The method of claim 2, wherein the procedure comprises balloon angioplasty or stent implantation.
- 4. The method of claim 3, wherein the procedure comprises stent implantation, and said administration is effective to inhibit intrastent restenosis.
- 5. The method of claim 1, wherein said administration is carried out without application of external stimulation to said composition during or following administration.
- 6. The method of claim 1, wherein the antirestenotic compound is selected from rapamycin, tacrolimus, and active analogs or derivatives or prodrugs thereof.
- 7. The method of claim 6, wherein the antirestenotic compound is selected from the group consisting of rapamycin, tacrolimus, and paclitaxel.
- 8. The method of claim 7, wherein the antirestenotic compound is rapamycin.
- 9. The method of claim 1, wherein the composition further comprises, conjugated to said carrier, an antiinflammatory compound, a compound effective to inhibit collagen accumulation or calcification of the vascular wall, or a combination thereof.
- 10. The method of claim 1, wherein the carrier is an aqueous suspension of insoluble gas-containing microbubbles.
- 11. The method of claim 10, wherein the gas is SF6 or a perfluorocarbon gas.
- 12. The method of claim 11, wherein the gas is selected from perfluoromethane, perfluoroethane, perfluoropropane, perfluorobutane, and perfluoropentane.
- 13. The method of claim 10, wherein the aqueous suspension contains at least one filmogenic compound selected from a protein, surfactant, lipid, polysaccharide, and combinations thereof.
- 14. The method of claim 8, wherein the carrier is a suspension of perfluorocarbon gas-containing microbubbles in an aqueous vehicle.
- 15. The method of claim 14, wherein the aqueous vehicle comprises at least one filmogenic compound selected from a protein, surfactant, lipid, polysaccharide, and combinations thereof.
- 16. The method of claim 15, wherein the vehicle contains human serum albumin and dextrose.
- 17. A method of inhibiting intrastent stenosis formation, at regions proximal and distal to an implanted stent in a blood vessel, comprising:
administering to a vessel in which such a stent is implanted, a composition comprising an antirestenotic compound conjugated to a microparticle carrier, wherein the microparticle carrier comprises a suspension of insoluble gas-containing microbubbles or biocompatible polymeric microparticles in a pharmaceutically acceptable liquid vehicle, wherein said administering is effective to inhibit intrastent stenosis formation.
- 18. The method of claim 17, wherein the antirestenotic compound is selected from the group consisting of rapamycin, tacrolimus, paclitaxel, active analogs or derivatives or prodrugs thereof, an antisense oligonucleotide having an antiproliferative effect, and combinations thereof.
- 19. The method of claim 17, wherein said administration is carried out prior to, during, and/or following implantation of the stent.
- 20. The method of claim 17, wherein said administration is carried out without application of external stimulation to said composition during or following administration.
- 21. The method of claim 17, wherein the antirestenotic compound is selected from rapamycin, tacrolimus, and active analogs or derivatives or prodrugs thereof.
- 22. The method of claim 21, wherein the antirestenotic compound is rapamycin.
- 23. The method of claim 17, wherein the carrier is a suspension of perfluorocarbon gas-containing microbubbles in an aqueous vehicle.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. Ser. No. 10/138,589 filed on May 3, 2002, which is incorporated herein in its entirety by reference.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10138589 |
May 2002 |
US |
Child |
10190419 |
Jul 2002 |
US |